DIETARY SUPPLEMENTS
Découvrez 08 - Slim
Your ally for a slimmer figure and healthy weight
Journal
What if we could send skin a message telling it that it is time to rebuild its extracellular matrix?
That, greatly simplified, is the idea behind one of the most fascinating categories of anti-aging peptides in skincare: signal peptides.
Over the past several years, peptides have become ubiquitous in serums and creams designed to target wrinkles, loss of firmness and visible skin aging. Among them, one name has become particularly prominent:
Matrixyl®.
Search for the best peptides for wrinkles, peptides for collagen production, Matrixyl benefits, or anti-aging peptides, and you will quickly encounter some remarkable claims.
Matrixyl is said to stimulate collagen production, activate fibroblasts, rebuild the extracellular matrix, improve skin firmness and reduce wrinkles.
But behind the name Matrixyl lies a scientific story far more interesting than the simple idea of a “collagen booster.”
It begins with just five amino acids:
Lys-Thr-Thr-Lys-Ser.
Or:
KTTKS.
This tiny sequence comes from a protein almost everyone has heard of:
type I collagen.
Its discovery helped establish a fascinating concept: some fragments derived from our own extracellular matrix may act as biological messages, influencing the behavior of the cells responsible for maintaining that matrix.
These bioactive fragments are known as:
matrikines.
From this came an idea that would become central to modern peptide skincare:
Could we reproduce some of the skin’s own molecular signals to encourage fibroblasts to produce components of the extracellular matrix?
That is the biological concept behind Matrixyl and a number of the signal peptides used in skincare today.
But the reality is more complex.
Between a collagen-derived peptide stimulating a fibroblast in a laboratory and a topical serum visibly reducing wrinkles on a human face, several major hurdles remain.
The peptide has to be biologically active.
It has to remain stable.
It has to penetrate the skin.
It has to reach the relevant cells.
And the biological response has to be large enough to produce a clinically measurable result.
So can a peptide really tell fibroblasts to make more collagen?
The scientific answer is far more interesting than a simple yes or no.
A peptide is a short chain of amino acids.
Proteins are also made of amino acids, but they may contain hundreds or thousands of them and fold into highly complex three-dimensional structures.
Peptides are generally much smaller.
But small does not mean biologically insignificant.
Quite the opposite.
Throughout the human body, peptides are involved in cell signaling and biological communication.
They can act as messengers, interact with receptors, influence signaling pathways and modify cellular behavior.
In skincare, the term signal peptide is commonly used for peptides designed to influence cellular processes, particularly those associated with the synthesis and remodeling of the extracellular matrix.
Conceptually, this distinguishes them from other major categories of cosmetic peptides, including:
Matrixyl belongs primarily to the first category:
signal peptides.
Because fibroblasts are among the most important cells in the dermis.
They participate in the production, organization and renewal of essential components of the extracellular matrix, including:
The extracellular matrix should not be thought of as passive filler between cells.
It is an extraordinarily complex and highly organized biological architecture.
It contributes to the mechanical properties of tissue, but it also participates in communication between cells and their surrounding environment.
Fibroblasts therefore do not exist independently of the matrix.
They build it.
They remodel it.
But they also receive information from it.
And this is where the story of matrikines begins.
For decades, the extracellular matrix was viewed primarily as a structural framework.
Today, we know that it is also an important source of biological signals.
When extracellular matrix proteins are broken down by enzymes, they can release peptide fragments.
Some of these fragments are not biologically inert.
They can interact with cells and alter cellular behavior.
These bioactive fragments derived from extracellular matrix proteins are called:
matrikines.
The concept is fascinating because it changes the way we understand tissue remodeling.
Breaking down the extracellular matrix does not simply produce biological debris that needs to be cleared away.
It may also generate information.
In simplified terms:
extracellular matrix → breakdown → peptide fragments → cellular signal → matrix remodeling.
In other words, the extracellular matrix may participate in signaling its own repair and renewal.
One of the foundational studies in this field was published by Katayama and colleagues in the Journal of Biological Chemistry in 1993 [1].
The researchers investigated a fragment derived from type I procollagen.
Collagen is not synthesized immediately in the final form found within the extracellular matrix.
Cells first produce precursor molecules, including procollagen, which then undergo several processing steps before mature collagen fibers are assembled.
During these processes, fragments can be released.
The researchers examined the activity of a fragment from the C-terminal propeptide of type I collagen and progressively narrowed it down to identify the minimal sequence responsible for its biological activity [1].
They arrived at five amino acids:
Lys-Thr-Thr-Lys-Ser
or:
KTTKS.
In their experimental model, this short sequence was able to stimulate the production of several components of the extracellular matrix [1].
In cultured human fibroblasts, KTTKS was associated with increased production of:
type I collagen;
type III collagen;
fibronectin [1].
This is a particularly important finding.
KTTKS was not an arbitrary sequence invented in a cosmetic laboratory.
It was derived from a structural protein within our own extracellular matrix.
The concept that followed was one of biological feedback.
During collagen remodeling, certain fragments may be released and potentially contribute to signaling that tells fibroblasts the extracellular matrix needs to be renewed.
Highly simplified:
collagen is remodeled → a fragment is released → the fibroblast receives a signal → extracellular matrix production increases.
This concept helped drive much of the scientific interest in matrikines and signal peptides for skin aging.
It is a useful way to explain the concept.
Scientifically, however, the word “tell” should not be taken too literally.
A fibroblast receives and integrates a huge number of biological signals simultaneously.
Growth factors.
Cytokines.
Hormones.
Mechanical tension.
Interactions with the extracellular matrix.
Oxidative stress.
Inflammatory signals.
Peptide fragments.
The cell’s final behavior reflects the integration of this complex biological environment.
A signal peptide is therefore not a simple switch:
OFF → ON.
It is better understood as one potential element capable of modulating a network of cellular signaling pathways.
That is considerably more complicated than a skincare slogan.
It is also considerably more interesting.
Because aging profoundly alters the extracellular matrix.
In younger skin, fibroblasts exist within a relatively dense and organized collagen-rich matrix.
With intrinsic aging and photoaging, this architecture progressively changes.
Collagen fibers become increasingly fragmented.
Dermal organization deteriorates.
The mechanical environment surrounding fibroblasts changes.
And the relationship between fibroblasts and their extracellular matrix works in both directions.
Fibroblasts produce the matrix.
But the matrix also influences fibroblasts.
When a fibroblast loses some of its mechanical interactions with a well-organized collagen network, its behavior can change as well.
This helps explain why dermal aging can become a self-reinforcing process:
damaged matrix → altered fibroblast environment → altered matrix production and remodeling → further matrix deterioration.
The possibility of using molecular signals to influence fibroblast behavior therefore becomes particularly compelling.
At this point, we have a biologically interesting sequence:
KTTKS.
But there is a major problem.
Human skin is specifically designed to keep outside molecules out.
The outermost portion of the epidermis, the stratum corneum, is an extraordinarily effective biological barrier.
And KTTKS is a relatively hydrophilic peptide.
In other words, biological activity in a cell-culture dish is not enough.
To become a useful topical skincare ingredient, the peptide must also be delivered into the skin.
This is where one crucial chemical modification enters the story:
palmitoylation.
Pal-KTTKS is KTTKS with a lipid chain derived from palmitic acid attached to it.
The resulting molecule is:
Palmitoyl Pentapeptide-4.
This is the molecule historically associated with:
Matrixyl®.
One purpose of this modification is to increase the molecule’s lipophilic character, potentially improving its interaction with the lipid-rich environment of the skin barrier.
This is a broader strategy used in peptide and medicinal chemistry:
modify the molecule to modify its delivery.
But that immediately raises another question:
Does it actually work?
A 2014 study directly compared KTTKS with Pal-KTTKS in an experimental skin-permeation model [2].
Researchers investigated their stability and ability to penetrate different layers of hairless mouse skin using Franz diffusion cells.
The results were particularly instructive.
Unmodified KTTKS was not detected in any of the analyzed skin layers.
Pal-KTTKS, however, was detected in:
In this model, adding the lipid chain dramatically changed the peptide’s cutaneous distribution.
Importantly, a small but measurable amount of Pal-KTTKS reached the dermis.
That matters because dermal fibroblasts are among the theoretical cellular targets of signal peptides.
No.
And that distinction matters.
In this experiment, neither KTTKS nor Pal-KTTKS was found at quantifiable levels in the receptor compartment beneath the skin [2].
The study therefore does not show that Pal-KTTKS passes freely or massively through the entire skin barrier.
Rather, it shows that palmitoylation produced substantially greater skin penetration and retention, with a measurable fraction of Pal-KTTKS reaching the dermis in this experimental model [2].
That is much more precise than simply saying:
“Palmitoylation makes peptides penetrate the skin.”
The evidence supports a narrower statement:
In an experimental skin model, palmitoylation substantially improved KTTKS penetration and retention and allowed a measurable amount of the peptide to reach the dermis.
In this experimental model, yes.
Researchers also found that both KTTKS and Pal-KTTKS were susceptible to proteolytic degradation, but Pal-KTTKS showed greater stability [2].
This highlights another major challenge in peptide skincare.
A peptide may be highly active when placed directly in contact with a cell in a laboratory.
But inside a cosmetic formulation and on human skin, it has to survive multiple potential sources of degradation:
temperature,
pH,
oxidation,
interactions with other ingredients,
enzymatic activity within the tissue.
Developing an effective cosmetic peptide therefore involves much more than identifying a biologically active amino-acid sequence.
Scientists also have to solve the problems of stability, formulation and skin delivery.
This is probably one of the most common misconceptions surrounding Matrixyl and anti-aging peptides.
Matrixyl® and Matrixyl 3000® are not the same thing.
The original Matrixyl is historically associated with:
Palmitoyl Pentapeptide-4 — Pal-KTTKS.
Matrixyl 3000 combines two different peptides:
Palmitoyl Tripeptide-1
and
Palmitoyl Tetrapeptide-7.
The names are similar.
The underlying concepts may overlap.
But the molecules are different.
This means that a study performed on Pal-KTTKS cannot automatically be used as evidence for Matrixyl 3000.
And vice versa.
That distinction is essential when evaluating the scientific evidence behind peptide skincare.
Because “Matrixyl” is often treated as though it were a single generic ingredient, when in reality different Matrixyl technologies involve different peptides.
Search online and you will find claims involving:
wrinkle reduction,
collagen production,
improved firmness,
increased hyaluronic acid,
greater skin density,
extracellular matrix repair.
Those results may then be attributed interchangeably to:
Matrixyl, Matrixyl 3000, Palmitoyl Pentapeptide-4, Palmitoyl Tripeptide-1 or Palmitoyl Tetrapeptide-7.
Scientifically, that is not appropriate.
Every claim should be traced back to:
the exact peptide studied,
its concentration,
the formulation used,
the experimental model,
and
the type of study performed.
An in vitro finding involving Pal-KTTKS does not automatically become clinical evidence for Matrixyl 3000.
That is probably the most common way Matrixyl is described.
But it oversimplifies the science.
The foundational KTTKS study did not look only at collagen.
It also reported effects involving fibronectin [1].
More broadly, the entire concept of matrikines is based on the ability of extracellular matrix-derived fragments to influence cellular behavior.
The more scientifically interesting idea is therefore not simply:
“put more collagen into the skin.”
It is:
“use molecular fragments inspired by the extracellular matrix to influence the cellular mechanisms involved in its renewal.”
That is much closer to the underlying biology.
Not necessarily.
This is arguably the most important distinction in the entire article.
We need to separate three different levels of evidence.
Level 1 — Mechanistic evidence:
A peptide modifies fibroblast behavior in vitro.
Level 2 — Tissue evidence:
The peptide actually increases a component of the extracellular matrix in living human skin.
Level 3 — Clinical evidence:
That biological change produces a visible and measurable outcome — such as reduced wrinkles.
These levels may be connected.
But they are not interchangeable.
A cell-culture study is not automatically clinical proof.
And a visible reduction in wrinkles does not automatically prove that the effect resulted from a histologically demonstrated increase in dermal collagen.
This is where the story becomes particularly interesting.
Unlike many cosmetic peptides for which human evidence remains extremely limited, Pal-KTTKS has been evaluated in a randomized, double-blind, vehicle-controlled human clinical trial [3].
The study involved:
93 women between the ages of 35 and 55.
For:
12 weeks.
And the study design was particularly useful.
Each participant applied a Pal-KTTKS-containing moisturizer to one side of the face and the same vehicle without the peptide to the other side [3].
In other words:
each participant served, in part, as her own control.
The concentration of Pal-KTTKS was only:
3 ppm.
And the results?
They deserve to be examined carefully.
Because this trial provides one of the most important pieces of human clinical evidence in the entire scientific history of Matrixyl.
We saw in Part 1 that the science behind Matrixyl is built around an elegant idea: reproduce a fragment derived from procollagen that can act as a biological signal, then chemically modify that peptide to improve its delivery into the skin.
But an elegant biological mechanism is not enough.
The real question is:
What happens on an actual human face?
In 2005, Robinson and colleagues published a clinical trial in the International Journal of Cosmetic Science evaluating Pal-KTTKS — Palmitoyl Pentapeptide-4, the peptide historically associated with Matrixyl® [3].
The study included:
93 Caucasian women between the ages of 35 and 55.
Over:
12 weeks.
The study was:
randomized;
double-blind;
vehicle-controlled;
and, importantly:
split-face.
Each participant applied a control moisturizer to one side of her face and the same moisturizer containing 3 ppm Pal-KTTKS to the other side [3].
This design is particularly useful because it reduces some of the variability that naturally exists between individuals.
Two people can have very different levels of photoaging, sun exposure, genetics, skincare habits and lifestyle factors.
Here, the comparator was literally on the other side of the same face.
After 12 weeks, the side treated with Pal-KTTKS showed a significant improvement in fine lines and wrinkles compared with the side receiving the vehicle alone [3].
The difference was observed through:
The peptide was also well tolerated.
So we have something important here:
A topically applied signal peptide produced a statistically significant anti-wrinkle benefit beyond that of the same vehicle without the peptide in a controlled human trial.
That represents a substantially stronger level of evidence than a fibroblast experiment alone.
No.
And this is exactly where we need to resist one of the most common scientific leaps in peptide skincare.
The trial demonstrated a clinical improvement in fine lines and wrinkles.
It did not directly demonstrate that a specific amount of new collagen had been synthesized within the participants’ dermis.
To establish that claim more convincingly, we would ideally need accompanying biological or histological measurements demonstrating changes in the human dermal extracellular matrix that correspond with the clinical improvement.
We therefore have two sets of evidence:
in the laboratory: KTTKS can stimulate certain components of the extracellular matrix [1];
in humans: Pal-KTTKS can improve certain measures of fine lines and wrinkles in a controlled clinical trial [3].
Those findings are biologically compatible.
But they do not directly prove the entire chain:
topical application → skin penetration → fibroblast signaling → increased dermal collagen → wrinkle reduction.
Parts of that chain remain mechanistic interpretation.
This is another important question.
The study reported a significant improvement in fine lines and wrinkles compared with the vehicle, but the way Matrixyl is sometimes marketed can create the impression of a dramatic transformation of the skin [3].
In science:
statistically significant does not necessarily mean visually dramatic.
A difference can be reproducible and statistically significant while remaining relatively modest in real-world appearance.
That does not diminish the value of the finding.
For a well-tolerated topical cosmetic active used for 12 weeks, demonstrating a measurable benefit beyond the vehicle is already meaningful.
But the result should be communicated at its actual scale.
No.
And that is relevant when evaluating the evidence.
The authors of the 2005 study were affiliated with The Procter & Gamble Company [3].
Industry affiliation does not invalidate a scientific study.
Cosmetic research frequently requires substantial industrial resources to develop formulations, fund clinical trials and perform sophisticated instrumental measurements.
But industry involvement remains relevant when assessing the overall body of evidence.
The ideal scientific progression is:
initial finding → independent replication → additional trials → different methodologies.
That is particularly important in cosmetic science, where ingredients can become commercially successful long before a large independent clinical literature develops.
Because it highlights a fundamental characteristic of signal peptides in skincare.
They are not necessarily intended to function at concentrations comparable with humectants or other ingredients commonly used at several percentage points.
A signal peptide is investigated for its ability to modify a biological response at relatively low concentrations.
In the Robinson et al. trial, Pal-KTTKS was used at just:
3 ppm [3].
This also challenges a widespread consumer assumption:
more peptide ≠ automatically more effective.
The relationship between concentration and biological response is not always linear.
For signaling molecules, there may be:
a minimum active concentration,
an optimal range,
a plateau,
or potentially different biological responses at much higher concentrations.
Comparing two peptide serums purely on the basis of the percentage printed on the label can therefore be scientifically misleading.
This is a critical question when shopping for Matrixyl serums.
In cosmetic formulation, a percentage given for a branded ingredient or proprietary complex does not necessarily represent the percentage of pure molecular peptide in the finished product.
A commercial raw material may itself contain:
the peptide,
water,
solvents,
humectants,
stabilizers,
preservatives.
So a claim such as:
“10% Matrixyl”
should not automatically be interpreted as:
“10% pure Pal-KTTKS.”
That distinction matters enormously when consumers attempt to compare commercial concentrations with concentrations used in scientific studies.
The 93-woman clinical trial evaluated:
Pal-KTTKS — Palmitoyl Pentapeptide-4.
It was not a clinical trial of:
Matrixyl 3000®.
Matrixyl 3000 combines:
Palmitoyl Tripeptide-1
and
Palmitoyl Tetrapeptide-7.
This may seem like a technical distinction.
It is not.
Online, findings from Pal-KTTKS studies are frequently used to support claims about Matrixyl 3000, while claims associated with Matrixyl 3000 are then used to describe Pal-KTTKS.
The result is an artificially inflated body of evidence in which data from different peptides become blurred together.
The scientific rule should remain simple:
each molecule should be evaluated on its own evidence.
Palmitoyl Tripeptide-1 is another palmitoylated peptide used within the broader category of signal peptides and matrikine-inspired skincare.
It is related to the GHK — Gly-His-Lys motif discussed in our article on GHK-Cu.
But there is a fundamental difference.
In GHK-Cu, the GHK peptide forms a complex with copper.
In Palmitoyl Tripeptide-1, GHK is associated with a palmitoyl chain intended, among other things, to modify its physicochemical properties and skin delivery.
GHK-Cu ≠ Pal-GHK.
They share the GHK sequence, but they are chemically distinct systems.
This is an excellent example of why peptide chemistry matters: modifying the same amino-acid sequence can significantly alter its behavior.
Palmitoyl Tetrapeptide-7 is the second peptide used in Matrixyl 3000.
It is generally positioned as complementing the matrix-related activity of Palmitoyl Tripeptide-1, including through mechanisms associated with cellular communication and the inflammatory environment.
But this is an area where scientific caution is particularly important.
Many highly specific claims about Palmitoyl Tetrapeptide-7 are repeated across commercial materials and secondary literature.
The body of independent primary research allowing those mechanisms to be examined in detail is much less extensive.
We should therefore distinguish between:
a proposed commercial mechanism
and
a mechanism robustly demonstrated by multiple independent research groups.
Experimental and commercial literature supports the hypothesis, and formulations containing Palmitoyl Tripeptide-1 and Palmitoyl Tetrapeptide-7 have been associated with changes in markers related to the extracellular matrix.
But the accessible literature does not justify simply transferring the strength of the 2005 Pal-KTTKS trial to Matrixyl 3000.
For example, a recent study of a topical anti-aging eye cream used:
0.0002% Palmitoyl Tripeptide-1
and
0.0001% Palmitoyl Tetrapeptide-7 [4].
Cellular analyses evaluated parameters associated with type I, III and IV collagen, elastin and fibronectin [4].
But the finished formula contained several other active ingredients.
It therefore cannot establish that every observed effect was caused specifically by the two peptides.
The same rule we applied to GHK-Cu applies here:
A clinical study of a cream containing a peptide is not necessarily a clinical study of the isolated peptide.
Imagine a cream containing:
Palmitoyl Tripeptide-1,
Palmitoyl Tetrapeptide-7,
niacinamide,
antioxidants,
humectants,
lipids,
botanical extracts.
After eight weeks, wrinkles improve.
What can we conclude?
That:
the formulation produced a result.
But not necessarily that:
Palmitoyl Tripeptide-1 produced the result.
And certainly not that:
Palmitoyl Tetrapeptide-7 alone produced the result.
To isolate the effect of a peptide, researchers ideally need to compare otherwise identical formulations in which the peptide itself is the primary variable.
That is one reason the 2005 Pal-KTTKS study design is so useful.
A 2026 systematic review and meta-analysis examined randomized controlled trials of peptides for skin aging [5].
In total, the researchers included:
19 randomized trials
involving:
1,341 participants [5].
But that number can be misleading without context.
Most participants received oral peptides, primarily collagen peptides.
Topical interventions represented only a small portion of the total evidence.
Overall, the meta-analysis found improvements in certain skin parameters and a modest pooled effect on wrinkles, but that benefit was driven largely by oral formulations [5].
Results for skin elasticity and density were less consistent.
The authors concluded that peptides remain a promising and generally well-tolerated approach, while emphasizing the need for:
larger randomized controlled trials,
standardized protocols,
and
histopathological evaluation [5].
That may be the most accurate snapshot of where the field currently stands.
Topical peptides are not unsupported by clinical evidence.
But their commercial reputation is far larger than the number of high-quality independent trials currently available.
This is one of the most common searches surrounding Matrixyl.
Scientifically, however, the comparison requires context.
Topical retinoids, particularly tretinoin, have several decades of clinical and histological research supporting their use in photoaged skin.
They have been studied for both visible outcomes and biological changes within the skin.
The evidence base for signal peptides is considerably smaller.
Current evidence therefore does not allow us to conclude that:
Matrixyl is more effective than retinol.
Nor can we conclude that it is clinically equivalent.
The two categories currently sit at very different levels of evidence.
Current evidence does not establish Matrixyl as a clinically proven replacement for retinoids.
Signal peptides may, however, represent a different biological approach to skin aging.
That can be particularly interesting in formulations designed for people who have difficulty tolerating more irritating skincare actives.
But:
potentially better tolerance ≠ equivalent efficacy.
Those are separate questions.
There is no universal scientific rule requiring Pal-KTTKS or the peptides used in Matrixyl 3000 to be separated from retinoids in every formulation.
The practical questions are formulation compatibility and overall skin tolerance.
A signal peptide and a retinoid do not necessarily act through the same biological pathways.
They could therefore theoretically be incorporated into the same anti-aging skincare strategy.
But demonstrating true synergy would require trials directly comparing:
retinoid alone,
peptide alone,
the combination,
and vehicle.
Without those data, “synergistic” remains a hypothesis rather than a demonstrated clinical fact.
Not necessarily.
Vitamin C — particularly L-ascorbic acid — plays distinct biological roles, including acting as a cofactor for enzymes involved in collagen biosynthesis and functioning as an antioxidant.
Signal peptides are instead designed to influence aspects of cellular communication associated with extracellular matrix renewal.
In simplified terms:
vitamin C → cofactor + antioxidant
while
signal peptide → potential biological signal.
Those mechanisms could be complementary.
But “complementary” does not automatically mean clinically synergistic.
This is a more biologically interesting comparison.
GHK-Cu is primarily considered a copper peptide — a peptide-metal complex with multiple experimental effects associated with tissue remodeling.
Pal-KTTKS is primarily studied as a signal peptide and matrikine.
Both can influence biological processes related to the extracellular matrix.
But their proposed mechanisms and clinical evidence differ.
So the most useful question is not simply:
Which peptide produces more collagen?
It is:
Which peptide, in which formulation, reaches which target, at what concentration, and with what demonstrated outcome in human skin?
They can be incorporated into the same broader skincare strategy, and multi-peptide formulations increasingly combine signal peptides, copper peptides and other peptide classes.
But whether a particular combination produces greater clinical benefit than either ingredient alone must be demonstrated for that specific formulation.
Simply combining two biologically interesting peptides does not automatically create synergy.
Peptide stacking refers to the increasingly common practice of combining several types of peptides in the same skincare routine or formulation.
A product might contain:
signal peptides,
copper peptides,
peptides targeting other biological pathways,
antioxidants,
hydrating ingredients.
The concept is attractive.
Skin aging is multifactorial, so targeting multiple mechanisms simultaneously may make biological sense.
But there is an important scientific paradox:
the more active ingredients a formulation contains, the harder it becomes to identify which ingredient produced the result.
A sophisticated cosmetic formulation is therefore not necessarily a clean scientific experiment.
They are generally regarded as relatively well-tolerated cosmetic actives, and Pal-KTTKS was well tolerated in the 12-week clinical study [3].
But a skincare product is never made of its hero peptide alone.
Tolerability also depends on:
the vehicle,
preservatives,
fragrance,
solvents,
other active ingredients,
pH.
Sensitive skin should therefore be evaluated against:
the complete formula.
Not simply the name of the peptide on the label.
This remains one of the central challenges in peptide skincare.
We saw that Pal-KTTKS reached the dermis in an experimental mouse-skin model, whereas unmodified KTTKS was not detected in the analyzed skin layers [2].
But the amount detected in the dermis was substantially lower than the amount retained in the stratum corneum.
And this was an experimental model, not normal daily application to human facial skin.
A recent review of matrikines highlights a recurring limitation in the peptide literature: direct skin penetration is not sufficiently characterized in many efficacy studies [6].
Delivery is therefore likely to remain one of the most important research areas for the next generation of topical peptides.
Theoretically, temporarily disrupting the skin barrier can increase the delivery of molecules that otherwise penetrate poorly.
But it also changes the safety equation.
A cosmetic serum formulated for intact skin is not automatically designed to be delivered deeper through microneedling.
Preservatives, solvents, excipients and purity become increasingly important when the barrier is deliberately disrupted.
The logic:
“the peptide does not penetrate well, so use microneedling”
is therefore not enough to constitute an evidence-based clinical recommendation.
Better delivery needs to be accompanied by evidence for:
efficacy, dose, delivery depth and safety.
Yes.
And this may be the most exciting part of the entire story.
KTTKS was identified in the 1990s by starting with knowledge of procollagen and progressively testing smaller peptide fragments [1].
Today, researchers can begin almost from the opposite direction.
They can analyze the matrisome — the complete set of proteins that make up and regulate the extracellular matrix — and use computational tools to predict which peptide fragments could be generated when specific proteases break those proteins down.
A 2024 study published in the British Journal of Dermatology used exactly this type of strategy [7].
Researchers combined:
computational prediction → peptide synthesis → human fibroblasts → transcriptomics → proteomics → human skin testing → clinical study.
The researchers began by analyzing extracellular matrix proteins in skin and predicting fragments that could theoretically be released through proteolytic cleavage [7].
The analysis identified:
453 potential matrikines.
Eight sequences were then selected for synthesis and experimental testing.
Two peptides emerged as particularly interesting:
GPKG — Gly-Pro-Lys-Gly
and
LSVD — Leu-Ser-Val-Asp [7].
As with KTTKS, the researchers palmitoylated these peptides to alter their cutaneous behavior:
Pal-GPKG
and
Pal-LSVD.
In human dermal fibroblasts, the peptides produced sequence-dependent biological effects [7].
Pal-GPKG increased parameters associated with procollagen I and several extracellular matrix components.
Pal-LSVD influenced markers including fibrillin-1 and decorin.
When used together, the two peptides altered the expression of numerous genes associated with extracellular matrix organization, collagen synthesis and repair-related processes [7].
The underlying idea is remarkably similar to the concept that led to KTTKS more than 30 years earlier:
Fragments inspired by our own extracellular matrix may influence the behavior of the cells responsible for maintaining that matrix.
But the discovery process has become dramatically more sophisticated.
The researchers did not stop at fibroblasts.
The peptide combination was first evaluated on human skin using histological and transcriptomic analyses.
Then:
38 women between the ages of 43 and 74
participated in a six-month split-face clinical study [7].
The peptide-containing formulation was associated with significant improvements in measurements of crow’s feet and skin firmness [7].
But once again, the authors acknowledged an important limitation:
the contribution of the peptides themselves, independently of the complete formulation, was not established [7].
The study also involved industry relationships. Several authors were employees of No7 Beauty Company or Sederma, and part of the research was funded by No7 Beauty Company [7].
That does not negate the findings.
It does reinforce the importance of independent replication.
Very likely, at least some of them.
A 2026 review describes the dramatic evolution of matrikine discovery and peptide research [8].
Historically:
known protein → experimental fragmentation → test individual fragments.
Today:
proteome → cleavage-site prediction → algorithms → molecular docking → machine learning → peptide selection → cell models → 3D skin models → human trials.
Future signal peptides may therefore be discovered by computationally analyzing the way our own extracellular matrix is fragmented during aging and tissue remodeling.
That represents a significant shift in the field.
It may instead be about understanding the molecular language of the extracellular matrix.
When collagen fibers, elastic proteins or other components of the matrix are remodeled, certain fragments may become biologically active.
Those fragments can potentially carry information.
And if we can identify:
which sequence,
which receptor,
which cell,
which concentration,
which tissue depth,
and
which biological response,
we may be able to design increasingly precise peptides.
Peptide skincare could therefore gradually move away from the simplistic concept of:
“collagen boosting”
toward:
targeted extracellular matrix signaling.
We can reasonably conclude that:
We still need robust evidence to determine:
Current evidence does not establish that:
The answer is far more interesting than either extreme.
The biological concept behind signal peptides is real.
KTTKS was not invented simply to give a sophisticated name to a face cream.
Its sequence comes from procollagen.
Its biological activity has been studied in fibroblasts.
Its modification into Pal-KTTKS improves its cutaneous penetration in an experimental model.
And Pal-KTTKS has human controlled-trial data demonstrating an improvement in fine lines and wrinkles [1–3].
It would therefore be inaccurate to dismiss Matrixyl as nothing more than cosmetic marketing.
But it would be equally inaccurate to turn these findings into the claim that a few drops of serum literally command the human dermis to rebuild its collagen.
The biological reality lies between those extremes.
And it is considerably more sophisticated.
For decades, anti-aging skincare focused largely on the surface of the skin.
Hydrate.
Smooth.
Exfoliate.
Protect.
Signal peptides introduce a different concept:
communicate with the cell.
KTTKS demonstrated that a sequence of just five amino acids derived from procollagen could alter fibroblast behavior [1].
Its transformation into Pal-KTTKS showed how chemistry could help address part of the skin-delivery problem [2].
And a controlled clinical trial demonstrated that this strategy could produce a measurable improvement in fine lines and wrinkles in humans [3].
That is not yet proof of complete reconstruction of the dermal extracellular matrix.
But it is no longer simply a laboratory hypothesis.
And more than 30 years after KTTKS, peptide research is moving much further.
Hundreds of potential fragments from our extracellular matrix can now be predicted computationally.
Their activity can be tested in fibroblasts.
Their biological signatures can be mapped through transcriptomics and proteomics.
And their effects can ultimately be evaluated in human skin [7,8].
So the question may no longer simply be:
“Can we tell fibroblasts to make more collagen?”
It may become:
“Can we understand the molecular language of the extracellular matrix well enough to send cells the right signal, in the right place, at the right concentration, at the right time?”
That may be where the true future of signal peptides lies.
Not in the simplistic promise to “boost collagen.”
But in a new generation of molecules designed to reproduce, with increasing precision, some of the signals our own skin uses to organize its maintenance, remodeling and repair.
Matrixyl® is historically associated with Palmitoyl Pentapeptide-4, also known as Pal-KTTKS, a signal peptide based on the KTTKS sequence derived from type I procollagen.
No.
Original Matrixyl is associated with Palmitoyl Pentapeptide-4.
Matrixyl 3000 combines Palmitoyl Tripeptide-1 + Palmitoyl Tetrapeptide-7.
Research on one should not automatically be used as evidence for the other.
A signal peptide is a short amino-acid sequence capable of influencing aspects of cellular communication. In skin-aging research, certain signal peptides are investigated for their ability to modulate fibroblasts and the synthesis or remodeling of extracellular matrix components.
A matrikine is a bioactive fragment derived from a protein in the extracellular matrix. Some matrikines can act as biological signals and modify cellular behavior [6].
KTTKS stimulated collagen production in experimental fibroblast models [1]. Pal-KTTKS has also demonstrated a clinical improvement in fine lines and wrinkles in a controlled human trial [3]. This does not mean that every product containing Matrixyl has been shown to produce a substantial increase in human dermal collagen.
A randomized, double-blind, vehicle-controlled, split-face trial involving 93 women found a significant improvement in fine lines and wrinkles after 12 weeks of using a formulation containing 3 ppm Pal-KTTKS compared with the vehicle [3].
The key clinical trial of Pal-KTTKS lasted 12 weeks [3]. That does not establish 12 weeks as a universal timeframe for every Matrixyl product, peptide concentration or formulation.
Current evidence does not support that conclusion. Retinoids have a substantially larger clinical and histological evidence base for photoaging.
Matrixyl has not been demonstrated to be a clinically equivalent replacement for retinoids. Signal peptides represent a different biological approach and may be useful in different skincare strategies.
There is no universal scientific rule prohibiting the combination. Tolerability and compatibility depend on the specific formulations and overall skincare routine.
There is no universal incompatibility established between all signal peptides and all forms of vitamin C. Stability and compatibility depend on the chemistry and formulation of the specific products.
Current evidence does not support a general clinical conclusion that one is superior to the other. They are different peptide systems and their evidence should be evaluated separately.
Not necessarily. Signal peptides can be biologically active at low concentrations, and advertised percentages may refer to a commercial raw-material complex rather than the concentration of pure peptide.
Skin penetration depends heavily on the peptide and its formulation. In one experimental model, Pal-KTTKS was detected as deep as the dermis, whereas unmodified KTTKS was not detected in the analyzed skin layers [2]. This finding cannot be generalized to every peptide or every cosmetic formulation.
They belong to different peptide categories and may be incorporated into the same skincare strategy. However, any claim of additional efficacy or synergy needs to be demonstrated for the specific combination and formulation.
After exploring peptide biology, GHK-Cu and signal peptides, our scientific investigation continues with a peptide family built around a radically different proposed mechanism:
ARGIRELINE & “BOTOX-LIKE” PEPTIDES — BOTOX IN A BOTTLE?
Acetyl Hexapeptide-8, the SNARE complex, neurotransmission, muscle contraction, expression lines and skin penetration.
An extraordinary promise.
And another opportunity to separate:
biological mechanism from clinical evidence.
A Doctor of Pharmacy and expert in Predictive & Preventive Medicine, Dr. ESPINASSE has spent more than 20 years developing an integrative approach connecting nutrition, metabolism, the microbiome, cellular function, aging and longevity.
Her clinical experience with more than 20,000 patients, informed by more than 15,000 in-depth assessments, led her to develop Cellular Nutrition®: an approach that considers nutrients and bioactive compounds through the physiological and cellular mechanisms they are intended to support.
Through METHODE ESPINASSE, Dr. ESPINASSE translates more than two decades of clinical experience into targeted nutritional protocols designed around health, beauty, longevity and healthy aging from within.
[1] Katayama K, Armendariz-Borunda J, Raghow R, Kang AH, Seyer JM. A pentapeptide from type I procollagen promotes extracellular matrix production. Journal of Biological Chemistry. 1993;268(14):9941–9944. PMID: 8486721.
URL: https://pubmed.ncbi.nlm.nih.gov/8486721/
[2] Choi YL, Park EJ, Kim E, Na DH, Shin YH. Dermal Stability and In Vitro Skin Permeation of Collagen Pentapeptides (KTTKS and palmitoyl-KTTKS). Biomolecules & Therapeutics. 2014;22(4):321–327. DOI: 10.4062/biomolther.2014.053.
URL: https://doi.org/10.4062/biomolther.2014.053
[3] Robinson LR, Fitzgerald NC, Doughty DG, Dawes NC, Berge CA, Bissett DL. Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin. International Journal of Cosmetic Science. 2005;27(3):155–160. DOI: 10.1111/j.1467-2494.2005.00261.x. PMID: 18492182.
URL: https://pubmed.ncbi.nlm.nih.gov/18492182/
[4] Comprehensive evaluation of the efficacy and safety of a new multi-component anti-aging topical eye cream. 2024.
URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC11208285/
[5] Nukaly HY, Halawani IR, Irtaza HM, et al. Oral and topical peptides for skin aging: systematic review and meta-analysis of randomized controlled trials. Frontiers in Medicine. 2026;13:1618306. DOI: 10.3389/fmed.2026.1618306. PMID: 41924746.
URL: https://pubmed.ncbi.nlm.nih.gov/41924746/
[6] Sirois JP, Heinz A. Matrikines in the skin: Origin, effects, and therapeutic potential. Pharmacology & Therapeutics. 2024;260:108682. DOI: 10.1016/j.pharmthera.2024.108682. PMID: 38917886.
URL: https://pubmed.ncbi.nlm.nih.gov/38917886/
[7] Jariwala N, Ozols M, Eckersley A, et al. Prediction, screening and characterization of novel bioactive tetrapeptide matrikines for skin rejuvenation. British Journal of Dermatology. 2024;191(1):92–106. DOI: 10.1093/bjd/ljae061.
URL: https://academic.oup.com/bjd/article/191/1/92/7610994
[8] Birtles T, El-Houni Z, Mistry K, et al. Bioactive peptide matrikines: discovery approaches for skin rejuvenation. American Journal of Physiology-Cell Physiology. 2026;330(4). DOI: 10.1152/ajpcell.00881.2025. PMID: 41770626.
URL: https://pubmed.ncbi.nlm.nih.gov/41770626/
[9] Abu Samah NH, Heard CM. Topically applied KTTKS: a review. International Journal of Cosmetic Science. 2011;33(6):483–490.
URL: https://pubmed.ncbi.nlm.nih.gov/?term=%22Topically+applied+KTTKS%22
[10] Birtles T, et al. Bioactive peptides in cosmetic formulations: current evidence and translational considerations. Peptides. 2025. DOI: 10.1016/j.peptides.2025.171440. PMID: 40946970.
URL: https://pubmed.ncbi.nlm.nih.gov/40946970/
